GM 1077
Alternative Names: AstenoseLatest Information Update: 15 Mar 1995
Price :
$50 *
At a glance
- Originator Glycomed
- Class Antihyperlipidaemics; Antithrombotics; Glycosaminoglycans; Vascular disorder therapies
- Mechanism of Action Glycosylation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis; Thrombosis
Most Recent Events
- 15 Mar 1995 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)